stocks logo

ELDN

Eledon Pharmaceuticals Inc
$
3.230
-0.39(-10.773%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.8195
Open
3.700
VWAP
--
Vol
1.56M
Mkt Cap
193.42M
Low
3.090
Amount
--
EV/EBITDA(TTM)
--
Total Shares
38.51M
EV
91.89M
EV/OCF(TTM)
--
P/S(TTM)
--
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.253
-73.21%
--
--
-0.257
-19.79%
--
--
-0.232
-78.14%
Estimates Revision
The market is revising No Change the revenue expectations for Eledon Pharmaceuticals, Inc. (ELDN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.22%.
EPS Estimates for FY2025
Revise Downward
down Image
-21.44%
In Past 3 Month
Stock Price
Go Down
down Image
-1.22%
In Past 3 Month
6 Analyst Rating
up Image
178.64% Upside
Wall Street analysts forecast ELDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELDN is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
178.64% Upside
Current: 3.230
sliders
Low
8.00
Averages
9.00
High
10.00
Craig-Hallum
NULL -> Buy
initiated
$12
2025-07-25
New
Reason
Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target.
Craig-Hallum
initiated
$12
2025-07-25
New
Reason
As previously reported, Craig-Hallum initiated coverage of Eledon Pharmaceuticals with a Buy rating and $12 price target. Eledon is developing tegoprubart to address the need for a new SOC in immunosuppression for kidney transplant patients, as current therapies cause kidney damage as a side effect, contributing to kidney graft failure after 10-15 years. The firm notes Tegoprubart's advantages support its potential to be the new SOC for kidney transplantation, which is a multi-billion dollar market opportunity, and it has broad utility in other organ transplant settings. Craig-Hallum sees opportunity for significant share appreciation with upcoming data catalysts in kidney transplantation including a Phase Ib update at WTC on August 6th, with readthrough to the Phase II topline readout in November, which represents a major de-risking event.
H.C. Wainwright
Yi Chen
initiated
$9
2025-06-19
Reason
H.C. Wainwright analyst Yi Chen assmed coverage of Eledon Pharmaceuticals with a Buy rating and $9 price target. Eledon is a clinical-stage biotechnology company focused on the development of an antibody targeting the CD40 ligand to prevent the rejection of transplanted organs and to treat neuroinflammation, the analyst tells investors in a research note. The firm says interim results from the Phase 1b trial demonstrated the company's lead candidate tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation.
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$16
2024-11-20
Reason

Valuation Metrics

The current forward P/E ratio for Eledon Pharmaceuticals Inc (ELDN.O) is -3.97, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Eledon Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.10
Current PE
-3.97
Overvalued PE
-0.66
Undervalued PE
-3.54

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.70
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.96
Undervalued EV/EBITDA
-9.36

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+65.28%
-17.96M
Operating Profit
FY2025Q1
YoY :
-72.51%
-6.50M
Net Income after Tax
FY2025Q1
YoY :
-89.87%
-0.08
EPS - Diluted
FY2025Q1
YoY :
+83.73%
-16.06M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 138.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
9.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ELDN News & Events

Events Timeline

2025-07-09 (ET)
2025-07-09
08:33:19
Sernova enters collaborative research agreement with Eledon Pharmaceuticals
select
2025-05-14 (ET)
2025-05-14
16:15:59
Eledon Pharmaceuticals reports Q1 EPS (8c), consensus (30c)
select
2025-01-13 (ET)
2025-01-13
06:25:07
Eledon Pharmaceuticals highlights recent business milestones, 2025 outlook
select
Sign Up For More Events

News

6.0
07-14NASDAQ.COM
New Strong Buy Stocks for July 14th
7.5
07-09Globenewswire
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
1.0
06-25Newsfilter
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Sign Up For More News

FAQ

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN) stock price today?

The current price of ELDN is 3.23 USD — it has decreased -10.77 % in the last trading day.

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s business?

arrow icon

What is the price predicton of ELDN Stock?

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s revenue for the last quarter?

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Eledon Pharmaceuticals Inc (ELDN)'s fundamentals?

arrow icon

How many employees does Eledon Pharmaceuticals Inc (ELDN). have?

arrow icon

What is Eledon Pharmaceuticals Inc (ELDN) market cap?